Infectious complications of antilymphocyte therapies in solid organ transplantation
- PMID: 19207081
- DOI: 10.1086/597089
Infectious complications of antilymphocyte therapies in solid organ transplantation
Abstract
Antilymphocyte therapies are widely used for immunosuppression in solid organ transplantation. These agents have varied mechanisms of action, with resulting differences in the intensity and duration of immunosuppression and in associated infectious complications. Induction therapy with antithymocyte globulins is associated with a greater incidence of cytomegalovirus, Epstein-Barr virus, and BK polyomavirus infections, compared with therapy with interleukin (IL)-2a receptor antagonists. However, long-term experience with the IL-2a receptor antagonists is lacking. By contrast, the treatment of graft rejection with T cell-depleting antibodies is associated with an increased risk of opportunistic infections. This is likely a reflection of the intensification of immunosuppression in the treatment of graft rejection and, often, a failure to link the use of antilymphocyte agents to prophylaxis for infection. The use of T cell-depleting agents, especially in the treatment of acute graft rejection, must be linked to monitoring and risk-adjusted prophylaxis for Pneumocystis, other fungi, Epstein-Barr virus, BK polyomavirus, and cytomegalovirus infection.
Similar articles
-
[Polyomavirus and tubulointerstitial nephropathy].Nephrologie. 2001;22(6):317-20. Nephrologie. 2001. PMID: 11715610 Review. French. No abstract available.
-
[Infectious complications due to immunosuppression in organ transplant patients].Rev Prat. 2007 Oct 15;57(15):1677-86. Rev Prat. 2007. PMID: 18080426 French.
-
Infection in the organ transplant recipient. An overview.Infect Dis Clin North Am. 1995 Dec;9(4):811-22. Infect Dis Clin North Am. 1995. PMID: 8747767 Review.
-
Induction of immunosuppression with polyclonal antithymocyte globulins: an overview.Exp Clin Transplant. 2003 Dec;1(2):79-84. Exp Clin Transplant. 2003. PMID: 15859913 Review.
-
[Infections in solid organ transplant recipients].Rev Invest Clin. 2005 Mar-Apr;57(2):368-80. Rev Invest Clin. 2005. PMID: 16524080 Review. Spanish.
Cited by
-
Impact of Immunosenescence in Older Kidney Transplant Recipients: Associated Clinical Outcomes and Possible Risk Stratification for Immunosuppression Reduction.Drugs Aging. 2024 Mar;41(3):219-238. doi: 10.1007/s40266-024-01100-5. Epub 2024 Feb 22. Drugs Aging. 2024. PMID: 38386164 Review.
-
Rabbit antithymocyte globulin (thymoglobulin): 25 years and new frontiers in solid organ transplantation and haematology.Drugs. 2010 Apr 16;70(6):691-732. doi: 10.2165/11315940-000000000-00000. Drugs. 2010. PMID: 20394456 Review.
-
The allo- and viral-specific immunosuppressive effect of belatacept, but not tacrolimus, attenuates with progressive T cell maturation.Am J Transplant. 2014 Feb;14(2):319-32. doi: 10.1111/ajt.12574. Am J Transplant. 2014. PMID: 24472192 Free PMC article.
-
Impact of Desensitization on Antiviral Immunity in HLA-Sensitized Kidney Transplant Recipients.J Immunol Res. 2017;2017:5672523. doi: 10.1155/2017/5672523. Epub 2017 Feb 6. J Immunol Res. 2017. PMID: 28265581 Free PMC article.
-
Rejection in Liver Transplantation Recipients.J Clin Exp Hepatol. 2024 Jul-Aug;14(4):101363. doi: 10.1016/j.jceh.2024.101363. Epub 2024 Feb 22. J Clin Exp Hepatol. 2024. PMID: 38495462
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical